Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
AMES, Iowa , April 24, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical
View HTML
Toggle Summary NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc.
View HTML
Toggle Summary NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster
View HTML
Toggle Summary NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as progress in its clinical development programs. The
View HTML
Toggle Summary NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
AMES, Iowa , Feb. 07, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The company has scheduled a conference call for 4:30 PM ET on the same day to
View HTML
Toggle Summary NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
AMES, Iowa , Jan. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company’s Chairman, CEO and Chief Scientific Officer, Charles J. Link, Jr , MD, will participate in the Immuno-Oncology 360 ° Conference (IO360 ° ) being held February 6 – 9, 2019 at
View HTML
Toggle Summary NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well
View HTML
Toggle Summary NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics’ Ebola vaccine candidate                AMES, Iowa , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) reported today that Merck has begun the
View HTML
Toggle Summary NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
AMES, Iowa , Nov. 09, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting in Washington D.C. Data from a Phase 1a clinical trial of NLG802 , a
View HTML
Toggle Summary NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
AMES, Iowa , Nov. 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society for Immunotherapy of Cancer (SITC) Conference 2018 website.
View HTML